Série de poudre brute d'amélioration du sexe de haute qualité Avanafil
La description:
Avanafil is a PDE5 inhibitor approved for erectile dysfunction by FDA . Avanafil acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors. It is absorbed quickly, reaching a maximum concentration in about 3045 minutes.
Usage:
It is a development of the phosphodiesterase type 5 inhibitors, for the treatment of male sexual dysfunction, at present in the America, EU and Japan have completed phase II clinical trials, phase III clinical trials will start. The product is composed of Japanese Tanabe Pharma Company and VIVUS company development. In addition to oral dosage forms, VIVUS company is also developing Avanafil urethral administration, for not responding to oral dosage forms of patients. Avanafil is a potent, highly selective phosphodiesterase 5 inhibitor, in vitro experiments showed that the selectivity of phosphodiesterase 5 stronger than sildenafil. The compound dear compliance weak against other phosphodiesterase, and effect of adenosine receptor decreased, suggesting that the cardiovascular effects of avanafil should be weaker than sildenafil. Pre clinical study showed that avanafil and organic nitrate drugs taken in combination to reduce its on blood pressure was significantly weaker than sildenafil and nitrate drugs with clothes. En outre, avanafil inhibition of phosphodiesterase 6 is very weak, the relevant visual disturbance suppression may the enzyme phosphodiesterase 5 inhibitor induced and other.
Dosage :
For most individuals, the recommended starting dose of avanafil is 100 mg per day taken about 30 minutes before sexual activity. Depending on the adequacy of the response or side effects, the dose may be increased to 200 mg or decreased to 50 mg a day. Individuals who are taking medications that moderately increase the blood levels of avanafil should not exceed a total dose of 50 mg in 24 heures.
Résultat du test de laboratoire:
Nom du produit |
Avanafil |
n ° CAS. |
330784-47-9 |
Emballage |
1KG/Bag |
Date de production |
2017/04/30 |
Durée de conservation |
2019/04/29 |
Standard |
IHS |
Articles |
spécification |
Résultats |
La description |
white or off white crystalline powder |
poudre cristalline blanche |
Solubilité |
soluble dans le diméthylsulfoxyde & slightly soluble in ethanol and methanol |
se conforme |
Identification,HPLC |
the principal peak in the chromatogram obtained with test solution is corresponds to retention time the principal peak in the chromatogram obtained with RS in the assay |
se conforme |
Point de fusion |
132-165?? |
163?? |
Métaux lourds |
not more than 10ppm |
se conforme |
Perte au séchage |
pas plus de 0.5% |
0.248% |
Une rotation optique spécifique |
-18.0 °to -26.0° |
-25.06° |
Methanol |
NMT 3000ppm |
se conforme |
Chloroform |
NMT 60ppm |
se conforme |
Cendres sulfatées |
pas plus de 0.1% |
0.05% |
Essai |
98-102% |
99.811% |
Conclusion |
Qualifié |
Sex Drug Raw Powder
|
Sildenafil Citrate (Viagra) |
Vardénafil |
Tadalafil (Cialis) |
Vardenafil HCL |
|
Yohimbine HCL |
HCL |
Avanafil |